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Abstract
Background: Polycystic ovary syndrome (PCOS) is a common yet underdiagnosed endocrinopathy with potentially serious sequelae. A screening questionnaire for PCOS can improve early identiﬁcation and diagnosis.
Objective: The purpose of this study was to test the utility of a self-administered questionnaire to help identify
women at risk for PCOS.
Study Design: We recruited women ages 18–50 with and without PCOS as deﬁned by modiﬁed Rotterdam
criteria to complete a self-administered survey of common PCOS signs and symptoms. The survey included questions regarding menstrual cycle characteristics and hyperandrogenism as measured by images from the
Ferriman-Gallwey (FG) scoring system, and by report of depilatory practices.
Results: Fifty-one women with PCOS and 50 women without PCOS participated in this study. Many study
participants were current users of hormonal contraceptives making it difﬁcult to discern menstrual cycle characteristics. Hirsutism, deﬁned by a modiﬁcation of the FG score of ‡3 from the upper lip and abdomen based on
self-assessments, provided a sensitivity of 76% and speciﬁcity of 70%, whereas report of any depilatory practices
provided a sensitivity of 71% and speciﬁcity of 74%. The combined sensitivity of these measures was 93% with a
speciﬁcity of 52%. In multivariate logistic regression, women who used depilatory techniques had an adjusted
odds ratio (aOR) of PCOS of 6.6 (95% conﬁdence interval [CI] 2.5–17.3, p = 0.0002). Those with obesity had similar
aOR of PCOS (aOR 6.7, 95% CI 2.5–17.9, p = 0.0001). Addition of other variables did not improve model ﬁt and the
net sensitivity and speciﬁcity of these two variables did not improve those of depilatory practices and hirsutism.
Conclusions: Self-report of depilatory practices or hirsutism is sensitive for identifying women with PCOS. Given
the prevalence of PCOS in reproductive-age women and the potentially serious health sequelae, it would be
worthwhile to include questions about terminal hair growth and depilatory practices when providing general
medical care to reproductive-age women to determine if further testing and screening for PCOS are indicated.
This tool may also be helpful in populations where complete diagnostic evaluation may not be feasible.
Keywords: depilatory; hyperandrogenism; polycystic ovary syndrome

Introduction
Polycystic Ovarian Syndrome (PCOS) is the most
common endocrinopathy affecting reproductive-age
women, with a prevalence ranging from 6% to 20%.1,2
PCOS is likely underdiagnosed, due, in part, to nonuni-

form diagnostic criteria, health care provider unfamiliarity, and diversity of PCOS phenotypes.3–5 In addition,
many women may not recognize that they have the condition and not seek appropriate evaluation and treatment. Moreover, all current diagnostic criteria require
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extensive diagnostic evaluation to exclude multiple conditions with overlapping presentation complicating both
clinical diagnosis and identiﬁcation of cases in large
population-based research studies in which ruling out
exclusion diagnoses may not be feasible.
Between 30% and 70% of women with PCOS are
obese,6,7 and PCOS has been associated with type 2
diabetes,8,9 hypertension,10 cardiovascular disease,9–11
anxiety,12,13 depression,13–15 infertility,16 and endometrial cancer.17 PCOS is associated with obstetrical risks,
including gestational diabetes and preeclampsia.18–20
Studies have also demonstrated increased risk for
children born to mothers with PCOS, including prematurity,18–20 neonatal intensive care unit admissions,19
attention-deﬁcit hyperactivity disorder, and autism
spectrum disorder.13 However, a study by Dokras et al.
showed that physicians are often unaware of these
health risks and cannot identify the appropriate diagnostic criteria for PCOS. This is more prevalent for
general gynecologists and those with fewer patients
with PCOS.21 Indeed, a large retrospective study found
that there was a lower prevalence of PCOS in primary
care clinics than in community samples, suggesting
underdiagnosis despite suggestive symptoms.22 Given
the long-term sequelae associated with PCOS, it is important to optimize the accuracy and frequency of diagnosis through screening and referral to appropriate
specialists.
To simplify clinical deﬁnitions of hirsutism, previous
studies have examined the utility of using only speciﬁc
portions of Ferriman-Gallwey (FG) index as predictors
of hirsutism. In 2000, Knochenhauer et al. examined
695 hyperandrogenic women and found that a hair
growth score ‡2 on the chin and lower abdomen was
a highly sensitive predictor for hirsutism.23 Examining
almost 2000 women, Cook et al. found that a hair
growth score of the chin, lower abdomen, and upper
abdomen ‡3 was able to accurately discriminate between hirsute and non-hirsute women at the same
level as a modiﬁed FG score of >7.24 These simpliﬁcations of the FG index would render clinical evaluations
less invasive. However, they also would allow for easier
self-evaluation.
In addition, a questionnaire that identiﬁes women
who should undergo diagnostic workup for PCOS
could reduce the number of women who go undiagnosed and untreated. Furthermore, a questionnaire
for identifying PCOS would be useful in epidemiological studies of female reproductive health as such a
questionnaire could be administered to large popula-
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tions of women without requiring expensive visits
and blood work to diagnose the condition.
The goal of this study is to utilize simpliﬁcations
of the FG index to evaluate the efﬁcacy of a selfadministered questionnaire in distinguishing women
at risk of PCOS.
Methods
Participants subjects
One hundred and one women 18–50 years of age were
enrolled in St. Louis, MO, based on PCOS status. Fifty
participants were recruited from the PCOS clinic at
Washington University School of Medicine and had
been previously diagnosed with PCOS, as deﬁned by
the modiﬁed Rotterdam criteria, including two of the
following three features: clinical or biochemical signs
of hyperandrogenism, polycystic appearing ovaries on
ultrasound, and/or oligo-ovulation or anovulation.25
The remaining 51 participants were women who had
never been diagnosed with PCOS and were recruited
from the Washington University School of Medicine
infertility clinic, local gynecology ofﬁces, and the
community through a research registry.
For inclusion, conﬁrmation of PCOS diagnosis was
made through medical chart review. At the time of enrollment, women were informed that the purpose of
the study was to help develop a screening questionnaire
for PCOS. Exclusion criteria included inability to provide
informed consent and non-English speakers. This study
was approved by the Washington University Human
Research Protection Ofﬁce (IRB no. 201510026).
Survey
Participants meeting study inclusion requirements
were asked to complete a survey, which contained
questions pertaining to the most common symptoms
of PCOS. In addition, they were asked information
about age, race, ethnicity, height, and weight if a current body mass index (BMI) was not available in the
medical record.10,26 Survey responses were entered
and stored on REDCap.27
Menstrual cycle characteristics. Women were asked
to characterize their menstrual cycle length and regularity and use of contraceptive methods, including all
forms of hormonal contraception or long-acting reversible contraceptives. Women using these forms of
contraception (n = 53) and women who had been pregnant in the previous 6 months (n = 4) were excluded
from analyses of cycle pattern.
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Symptoms of hyperandrogenism. Women were
asked about the presence of acne in the last 3 months.
They were able to choose ‘‘no acne,’’ ‘‘1–4 pimples,’’ and
‘‘5 or more pimples’’ on cheeks, chin, and forehead.
Acne severity was deﬁned as ‘‘no acne,’’ ‘‘physiological
acne,’’ or ‘‘clinical acne,’’ respectively, based on modiﬁed deﬁnitions from Poli et al.28
Women were asked whether they had ever used laser
hair removal ‘‘in body parts other than bikini line, legs,
or underarms.’’ They were also asked whether they
had ever shaved, waxed, or bleached hair outside the
previously mentioned areas. In addition, they were presented with images from the FG index to rate terminal
hair growth in different body regions. Each region contained ﬁve images, the four original FG images as well
as an FG image modiﬁed terminal hair to signify ‘‘no
hair growth’’ (Fig. 1). Women selected the image corresponding to the extent of their terminal hair growth in
the six body regions from the nine regions in the modiﬁed FG scale that are easiest to self-assess and most
strongly associated with hirsutism: upper lip, chin,
chest, upper and lower abdomen, and thighs.23,29
Hirsutism was deﬁned by the simpliﬁed FG (sFG)
score, or the sum of individual scores of the upper
lip, lower abdomen, and upper abdomen, If the total
sFG score was greater or equal to 3, the woman was
considered to have hirsutism.24
Statistical analysis
Chi-square, Fisher’s exact, and Wilcoxon rank-sum
tests were used to compare cases and controls, when
appropriate. The sensitivity and speciﬁcity for sFG, individual body regions,23 and depilatory practices in
identifying PCOS were calculated. To evaluate the use
of multiple screening questions concurrently, net sensitivity and speciﬁcity were calculated for hirsutism and
use of depilatory practices. Net sensitivity and speciﬁcity were calculated for the combined body regions of
the lower abdomen and chin as described in Knochenhauer et al.23 To calculate the positive and negative
predictive values of questions in the questionnaire,
prevalence of hirsutism in PCOS was deﬁned as 70%30
and prevalence of PCOS in the population was deﬁned
as 5%–15%.5
To evaluate the merit of including multiple variables
in screening, we performed a stepwise multiple logistic
regression, including the following characteristics: obesity, as deﬁned by BMI ‡30 kg/m2, use of depilatory
practices, hirsutism as deﬁned by sFG, and presence
of clinical acne.
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For all analyses, p < 0.05 was considered statistically
signiﬁcant. SAS Version 9.4 (SAS Institute, Inc., Cary,
NC) was used for all analyses.
Results
Fifty-one women with PCOS and 50 women without
PCOS were enrolled in the study. There were no significant differences in age or contraceptive use between
groups (Table 1). The majority of women with PCOS
identiﬁed as white, whereas women without PCOS
were more heterogeneous; however, this difference was
not statistically signiﬁcant. Women with PCOS had a
median BMI of 32 kg/m2, and 67% were obese. The
median average BMI for women without PCOS was
signiﬁcantly lower at 25 kg/m2 ( p < 0.0001), and only
22% were obese.
Women with PCOS were more likely to have clinical
acne than women without PCOS and were more likely
to use depilatory techniques to remove terminal hair
growth. When examining only women who were not
using hormonal contraception (n = 24 PCOS and 24
non-PCOS women), women with PCOS were more
likely to have menstrual irregularity (55% vs. 10%;
p = 0.003). The majority (73%) of women with PCOS
met criteria for hirsutism by sFG ‡3. For women
with PCOS, 89% of those using combined oral contraceptives (COCs) and 63% not using oral contraceptives
(OCPs) met criteria for hirsutism, but this difference
was not statistically signiﬁcant.
While a high percentage (28%) of non-PCOS women
met criteria for hirsutism, the average total sFG was
signiﬁcantly higher in women with PCOS than in controls ( p < 0.0001). Women with PCOS had signiﬁcantly
higher FG scores for terminal hair growth based on the
modiﬁed FG images than non-PCOS women for all regions, except chest and upper abdomen. However, the
median score for these regions for both cases and controls was low (Table 1).
The sensitivity and speciﬁcity of using sFG ‡3 for
identifying PCOS were 76% and 70%, respectively
(Table 2). Participating in any depilatory practice had
similar sensitivities and speciﬁcities. When these two
screening questions were combined, the net sensitivity
was high at 93%, but speciﬁcity decreased to 52%. For
regional terminal hair score of ‡1, sensitivities ranged
from 47% to 92% and speciﬁcities from 36% to 68%
(Table 2). As expected, as score cutoffs increased, sensitivities decreased and speciﬁcities increased (‡3 and
‡4, not shown). Net sensitivity and speciﬁcity for the
lower abdomen and chin scores of ‡1 were 98% and
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FIG. 1.

Ferriman-Gallwey images39 used for participant selection.
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Table 1. Demographic and clinical characteristics
by polycystic ovary syndrome diagnosis

Table 2. Sensitivity and speciﬁcity for polycystic ovary
syndrome diagnosis based on regional terminal
hair growth and depilatory practices

Characteristic

PCOS (51)

No PCOS (50)

Unadjusted
p-value

Age
BMI
Race
White
African American
Other

28 (25–33)
32 (28–39)

28.5 (23–35)
25 (22–30)

0.83
<0.0001

50 (98)
1 (2)
0 (0)

40 (87)a
4 (9)
2 (4)

0.08

Menstrual pattern
irregularityb
Contraception
COC

11 (55)

2 (10)

0.003

26 (50)
19 (37)

26 (50)
12 (24)

0.92
0.15

Depilatory practice
Electrolysis
Shave, wax, bleach

8 (16)
38 (75)

5 (10)
14 (28)

0.37
<0.0001

19 (37)

10 (20)

0.06

4 (3–6)
37 (76)

1 (0–3)
14 (28)

<0.0001
<0.0001

Clinical acnec
Hair
Total sFG
Hirsutism by sFG
Locations
Chin
Upper lip
Chest
Upper abdomen
Lower abdomen
Thigh

1
2
0
0
1
2

(1–2)
(1–3)
(0–1)
(0–1)
(2–3)
(1–3)

0
1
0
0
1
1

(0–1)
(0–1)
(0–1)
(0–1)
(0–1)
(0–2)

<0.0001
<0.0001
0.12
0.16
<0.0001
0.009

a

Four participants had unknown race.
b
For patients not using hormonal contraception or intrauterine
devices.
c
Clinical acne deﬁned as 5+ pustules on chin, cheeks, and forehead
within previous 3 months.
BMI, body mass index; COCs, combined oral contraceptive pills; PCOS,
polycystic ovary syndrome; sFG, simpliﬁed Ferriman-Gallwey Categorical
data represented as n (%), and continuous and integer variables represented as median (interquartile range).

24%, respectively. However, increasing the score to ‡2
increased speciﬁcity to 74%, whereas sensitivity only
decreased to 79%.
Positive predictive value (PPV) for identifying PCOS
using sFG ‡3 ranged from 0.11 to 0.31 (Table 3). PPV
ranges were similar for depilatory practices. The PPV
for parallel use of both questions was higher at 0.14–
0.36. Negative predictive values for these metrics were
signiﬁcantly higher.
Together, obesity and using depilatory practices were
signiﬁcant predictors for PCOS diagnosis (Table 4). Inclusion of additional variables, such as hirsutism, presence
of clinical acne, or menstrual irregularity in those not
on contraceptives, did not improve the ﬁt of the
model signiﬁcantly. R2 of the model was 0.41 and
c-statistic was 0.81. Given that over 50% of women in
our cohort were using contraception, analyses examining menstrual irregularity were not performed. Given
the signiﬁcance of these two predictors to the model,

Sensitivity (%)

Specificity (%)

76
71
93

70
74
52

76
93

70
52

78
47

58
92

Lower abdomen
‡1
‡2

92
61

41
80

Combined regionse
‡1
‡2

98
79

24
74

Upper lip
‡1
‡2

88
53

36
78

47
22

69
83

48
18

64
94

88
53

36
66

Hirsutisma
Depilatory practicesb
Hirsutism and depilatory
practices combinedc
Obesity
Obesity and depilatory
practices combinedd
Chin
‡1
‡2

Upper abdomen
‡1
‡2
Chest
‡1
‡2
Thighs
‡1
‡2
a

Hirsutism is deﬁned as sFG ‡3.
Depilatory practices include shaving, waxing, or bleaching hair, or
use of electrolysis on the face, chest, or abdomen.
c
Net sensitivity and speciﬁcity for hirsutism or depilatory practices.
d
Net sensitivity and speciﬁcity for obesity and depilatory practices.
e
Net sensitivity and speciﬁcity for combined body regions lower abdomen and chin.
sFG, simpliﬁed Ferriman-Gallwey index.
b

we also calculated the net sensitivity (93%) and speciﬁcity (52%) of obesity and the use of depilatory practices—
the same as for depilatory practices and hirsutism by
sFG. Therefore, the combinations of these questions
did not improve upon the PPV and negative predictive
value for hirsutism and depilatory practices.
Discussion
Principle ﬁndings
We found that asking women about their malepatterned hair growth and depilation practices through
a self-administered questionnaire has high sensitivity
and moderate speciﬁcity in predicting PCOS diagnosis,
making questions regarding these practices ideal for
PCOS screening.

Bedrick, et al.; Women’s Health Reports 2020, 1.1
http://online.liebertpub.com/doi/10.1089/whr.2020.0073

571

Table 3. Positive and negative predictive values
for hirsutism, depilatory practices, and combined
lower abdomen and chin regions by varying polycystic
ovary syndrome prevalence
Screening
a

Hirsutism

Depilatory practicesb
Combined questionsc
Lower abdomen and chin ‡1d
Lower abdomen and chin ‡2e

Prevalence (%)

PPV

NPV

5
10
15
5
10
15
5
10
15
5
10
15
5
10
15

0.12
0.22
0.31
0.11
0.21
0.29
0.14
0.26
0.35
0.15
0.27
0.37
0.12
0.23
0.32

0.98
0.96
0.94
0.98
0.96
0.94
0.99
0.99
0.98
0.996
0.99
0.99
0.99
0.97
0.95

a

Hirsutism as deﬁned by sFG.
Depilatory practices include shaving, waxing, or bleaching hair, or
use of electrolysis on the face, chest, or abdomen.
c
For net sensitivity and speciﬁcity of hirsutism or depilatory practices.
d
For net sensitivity and speciﬁcity of lower abdomen and chin each
‡1.
e
For net sensitivity and speciﬁcity of lower abdomen and chin each ‡2.
NPV, negative predictive value; PPV, positive predictive value.
b

Results
Consistent with previous work, the prevalence of hirsutism in our cohort of women with PCOS was 73%,30
and obesity was a strong predictor of PCOS.31,32 Positive responses for hirsutism as deﬁned by sFG or for depilatory practice had sensitivity and speciﬁcity of over
70%. Positive responses to both of these screening
questions gave a high sensitivity of 93%, but lower speciﬁcity at 52%.
Clinical implications
PCOS is associated with a myriad of poor health outcomes for women,8–20 as well as their offspring.13,18–20
In addition to poor health outcomes, women with
PCOS have lower markers of quality of life, both physically and psychologically when compared to agematched controls.33 It is estimated that PCOS costs
the United States health care system $4.4 billion dollars
throughout a woman’s reproductive lifespan. However,
Table 4. Multivariate logistic model for polycystic
ovary syndrome prediction
Variable

aOR

95% CI

p

Obesity
Depilatory practices

6.7
6.6

2.5–17.9
2.5–17.3

0.0001
0.0002

aOR, adjusted odds ratio; CI, conﬁdence interval.

only 2% of this cost is spent on initial evaluation.34 Furthermore, the diagnostic process for many women with
PCOS is inefﬁcient and unsatisfactory. Gibson-Helm
et al. found that more than 2 years and two health professionals were needed for accurate diagnosis of PCOS in
>33% of cases.35 In a large Australian cohort of women
with PCOS, quality of life was associated with perceived
quality of information given about their diagnosis.33
Gaps in physician knowledge about the risks of PCOS
and delays in diagnosis result in missed recommended
screenings, such as blood pressure, cholesterol, and hemoglobin A1C.36 Given the signiﬁcant delay in diagnosis and impact on quality of life and long-term health,
identiﬁcation of women at risk of PCOS is vital.
The FG scoring system for hirsutism currently relies
on physician evaluation. However, these examinations
are cumbersome and frequently prohibitive in epidemiological studies. In addition, when women use depilatory
techniques to remove hair, accurate evaluation by a physician may not be possible. Compared to more objective
measurements of hirsutism, such as photographic scoring or hair measurements, scoring by the FG method is
more subjective and has been shown to have high interobserver and intraobserver reliability.37,38
In 2005, Wild et al. asked 21 women with PCOS to
score themselves and be scored by three trained professionals. They found considerable variability in scoring
and concluded that self-scoring was not clinically useful. However, all scores were signiﬁcantly higher than 6,
indicating that all observers were in agreement that the
women met criteria for hirsutism.37
More recently, Pedersen et al. sought to validate a
questionnaire for use in the diagnosis of PCOS and
noted that a history of infrequent menses, hirsutism, obesity, and acne was strongly predictive of a diagnosis of
PCOS and developed a four-item questionnaire that
yielded a sensitivity of 77% and speciﬁcity of 94%. However, in contrast to our study presented here, they
recruited women with menstrual irregularity, hirsutism,
and infertility, which limit generalizability. They also
used the National Institutes of Health (NIH) diagnostic
criteria for PCOS, which requires oligo-ovulation or
anovulation and clinical or biochemical hyperandrogenism for diagnosis, which differs from our study.39
While self-evaluation may be less accurate than evaluation by a trained professional, this study demonstrates
that women can accurately determine whether they
have hirsutism. As a solution for high variability in scoring, Cook et al. introduced the simpliﬁed FG method,
which reduces the number of body regions evaluated,
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while still accurately diagnosing hirsutism.24 In our
study, we used the sFG to designate hirsutism; however,
we asked patients to evaluate themselves. Given that 37%
of generalists are unaware of the diagnostic criteria for
PCOS,21 self-screening questionnaires may be able to improve targeted referrals to specialists.
Research implications
Simple, self-administered questionnaires improve the
ability to conduct large epidemiological studies, as
they do not rely on expert evaluation. Implementation
of a questionnaire to screen for PCOS, which includes
questions about depilatory practices and hirsutism,
may help in epidemiologic studies of PCOS.
Strengths and limitations
We note three key strengths of this study. This adds to the
extremely limited literature that has examined the utility
of a screening questionnaire to identify women at risk for
PCOS. As a chronic disease with signiﬁcant long-term sequelae and lifestyle and medical interventions, PCOS is a
prime disease for a screening questionnaire. This screening test is both sensitive and speciﬁc and has a high negative predictive value. While the PPV was relatively low,
this reﬂects the overall prevalence of PCOS. Finally, the
questions do not rely on menstrual irregularity. Given
the large proportion of reproductive-age women who
use contraception and whose menstrual cycles may be
normalized or affected by these methods, it is vital that
a screening tool does not rely on menstrual regularity.
Several limitations of our study must be considered.
First, as with all case–control studies, recall and selection bias are two major considerations. For example,
women with PCOS who report to clinics may be
more symptomatic than women with PCOS who do
not present for evaluation. Therefore, the women
with PCOS in our study may be more symptomatic
than undiagnosed PCOS patients. In addition, as the
participants were not blinded to the purpose of the
study, their responses are subject to recall bias.
Second, our cohort predominantly identiﬁed as white,
which limits its generalizability. Given that terminal hair
growth can vary by race and ethnicity, it is important for
future studies to include a more heterogeneous sample.
Depilatory techniques are frequently employed for removal of eyebrow hair in women without hirsutism.
Our questionnaire did not speciﬁcally ask women if
their facial hair removal was in areas with male-patterned
growth, which may have led to falsely elevated proportions of women answering yes to this question.
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Third, for several participants, self-reported weight
and height were used to calculate BMI. While selfreported weight and height are not as precise as measurements conducted in clinic, they have been shown
to be accurate.26
Fourth, given the large portion of women on OCPs,
questions about menstrual cycle characteristics could
not be used in the ﬁnal model. Studies have remedied
this problem by excluding women on COCs. However,
exclusion of women on COCs biases results since symptomatic women are more likely to have been prescribed
COCs. Also, given that *40% of reproductive-age
women use some form of hormonal contraception or
long-acting reversible contraceptive,40 it is important
for a screening tool to identify individuals at risk of
PCOS without relying on questions about menstrual regularity. Furthermore, asking women to recall their menstrual cycle characteristics before initiating hormonal
contraception is not without limitations, including recall
bias, which will increase the longer a woman is on contraception. Furthermore, cycle characteristics several
years prior are not necessarily a good predictor of current
cycle characteristics. Therefore, while it would be ideal to
know current cycle characteristics of all women, this has
limited utility in a general population.
Conclusions
Straightforward self-screening questions on obesity,
depilatory practices, and male-patterned terminal hair
growth can aid in identifying women at risk for
PCOS. This has signiﬁcant implications for helping
women and physicians correctly identify who should
be further worked up for this endocrinopathy.
Condensation
A questionnaire capturing self-report of depilatory
practices and/or hirsutism is sensitive for identifying
women with PCOS.
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